<DOC>
	<DOCNO>NCT00441584</DOCNO>
	<brief_summary>This uncontrolled , non-randomized , open-label , multinational study design evaluate efficacy safety PegIntron plus Rebetol subject chronic hepatitis C. The study design determine proportion chronic hepatitis C genotype 1 subject respond previous treatment Pegasys 180µg QW plus ribavirin , achieve sustain virological response ( SVR ) treat PegIntron plus Rebetol .</brief_summary>
	<brief_title>The Effects PegIntron Plus Rebetol Subjects With Chronic Hepatitis C Not Responding Pegasys ( Study P03833 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Subject must demonstrate willingness participate study comply procedure sign write informed consent . Subject must 1870 year age either sex race . Subject must diagnose chronic hepatitis C genotype 1 ( confirmation biopsy require ) . ( Liver function test ( LFTs ) normal elevate . ) Female subject pregnant breastfeeding must either postmenopausal , surgically sterile use 2 method birth control . While abstinence sexual activity certain method prevent pregnancy , female patient childbearing potential anticipate possibility become sexually active male partner must use combination follow 2 method : Contraceptive pill intrauterine device ( IUD ) depot hormonal preparation ( ring , injection , implant ) , A barrier method contraception diaphragm , sponge spermicide , condom , method birth control consider acceptable study physician . Contraceptive measure review female subject visit . Dual method contraception must use 6 month treatment discontinuation . Female subject childbearing potential must negative serum pregnancy test screen phase study . Confirmation principal investigator subinvestigator sexually active male subject practice method contraception consider acceptable ( vasectomy , condom plus spermicide , plus relationship female partner practice acceptable method contraception ) . Contraception must use treatment period seven month completion therapy , include condom use male subject pregnant partner . Subject must free clinically significant disease would interfere study evaluation . Subject must understand , able agree adhere dose visit schedule . Compensated liver disease follow minimum hematologic biochemical criterion Day 1 visit within normal limit : Hemoglobin value equal great 12 g/dL female 13 g/dL male White blood cell ( WBC ) count equal great 3,000/cu mm Neutrophil count equal great 1,500/cu mm Platelet count equal great 80,000/cu mm Direct bilirubin within normal limit Indirect bilirubin within normal limit ( unless nonhepatitis related factor Gilbert 's disease explain indirect bilirubin rise ) . In case indirect bilirubin less equal 3.0 mg/dL ( less equal 51.3 µmol/L ) Albumin within normal limit Serum creatinine within normal limit Subject must nonresponder , define receive responded prior treatment consist one course Pegasys 180 mcg QW combination ribavirin 10001200 mg daily , without amantadine , minimum 12 week : Subject must find hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) positive less 2log drop 12 week treatment , polymerase chain reaction ( PCR ) positive End Of Treatment , whether End Of Treatment happen week 48 early Subject must Pegasys/ribavirin least 12 week prior screen . Subject must treatment interferon except Pegasys . Subject must neither receive currently treatment chronic hepatitis C disease , except amantadine . When available , historical liver biopsy pathology report subject must confirm histological diagnosis consistent chronic hepatitis C. Subject must value thyroid stimulate hormone within normal limit ( whether euthyroid require thyroid medication ) . Antinuclear antibody must less equal 1:320 . If abdominal imaging perform within 1 year prior screen , must show evidence focal mass suggestive hepatoma and/or ascites . For subject history diabetes hypertension , clearance ophthalmologist obtain prior treatment start . Subject female pregnant breastfeeding , intend become pregnant study . Subject use investigational product within 30 day prior enrollment currently involve another clinical trial . Subjects weigh 125 kg . Subject follow cause liver disease base subject history biopsy ( applicable ) chronic hepatitis C , include limited : Hemochromatosis Alpha1 antitrypsin deficiency Wilson 's disease Autoimmune hepatitis Alcoholic liver disease Nonalcoholic steatohepatitis ( NASH ) Drugrelated liver disease Subject clinically significant deviation normal physical examination , chest xray , electrocardiogram ( ECG ) , investigator 's judgment , may interfere study evaluation affect subject safety . Subject situation condition , opinion investigator , may interfere optimal participation study . Subject part staff family member staff personnel directly involve study . Subject previously untreated subject . Subject treat Pegasys + less 1000 mg ribavirin ( instead 10001200 mg ribavirin ) . Subject discontinued Pegasys treatment week due adverse event . Subject coinfected human immunodeficiency virus ( HIV ) and/or hepatitis B virus ( HBV ) . Subject suspect hypersensitive interferon alpha PegIntron ribavirin . Subject previously receive interferon , ( except Pegasys flat dose 180 mcg QW least 12 week ) , thymosin Cell Cept treatment drug intend treat chronic hepatitis C. Subject organ transplant cornea hair transplant . Subject history hepatocellular carcinoma malignancy ( except basal cell carcinoma ) within last 5 year suspect diagnosis hepatocellular carcinoma malignancy , active malignancy . Known coagulation diseases hemophilia ; hemoglobin disease ( e.g . thalassemia ) . Subject glucose6phosphate dehydrogenase ( G6PD ) deficiency . Subject evidence decompensated liver disease history presence ascites , bleed varix , spontaneous encephalopathy . Subject know preexist medical condition could interfere subject 's participation completion study follow : Preexisting psychiatric condition , especially moderate severe depression , history severe psychiatric disorder , psychosis , suicidal ideation , suicide attempt . Severe depression include follow : Hospitalization depression Electroconvulsive therapy depression , Depression cause prolonged absence work significantly alter daily function . Subjects mild depression may consider entry study provide pretreatment assessment demonstrate subject 's emotional status clinically stable , case management plan must formulate subject ; management plan become part subject 's medical record . Craniocerebral trauma , concussion , active seizure disorder require medication . Clinically significant ECG abnormality and/or cardiovascular dysfunction within 6 previous month ( e.g. , angina , congestive heart failure , recent myocardial infarction , significant arrhythmia ) . Chronic lung disease ( e.g. , chronic obstructive lung disease ) Poorly control diabetes mellitus : HbA1C equal 8.5 % Immunemediated disease ( e.g. , inflammatory bowel disease [ Crohn 's disease , ulcerative colitis ] , idiopathic thrombocytopenic purpura , systemic lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis ) Clinical gout Creatinine clearance less equal 50 mL/min medical condition may require use chronic systemic steroid Subject substance abuser , alcohol ( 80 g/day ) , methadone , intravenous ( IV ) , oral inhale drug . To consider inclusion , subject must abstain agree abstain use least 6 month . Subjects treat buprenorphine ( Subutex ) stable 6 month may include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>